Adagio Medical Inc. Closes Significant $19 Million Funding Round

Adagio Medical Holdings, Inc. has successfully secured $19,000,000 in a recent funding round. The medical device company, listed on Nasdaq under the ticker ADGM, has received this investment capital from a group of investors to further advance its pioneering work in the treatment of cardiac arrhythmias. Adagio Medical specializes in developing and commercializing products for treating cardiac arrhythmias. Its core technology is the proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) system. This innovative approach is engineered to create large, durable lesions that extend through the full depth of both diseased and healthy cardiac tissue. Currently, the company is focused on addressing ventricular tachycardia (VT) with its purpose-built vCLASTM Cryoablation System, which holds CE Mark approval and is actively being evaluated in the FULCRUM-VT U.S. IDE Pivotal Study. The $19,000,000 capital infusion is significant for Adagio Medical as it navigates critical development and commercialization phases for its specialized medical devices. The company plans to strategically deploy these funds to bolster its ongoing research and development efforts, particularly in advancing its Ultra-Low Temperature Cryoablation (ULTC) technology and the vCLASTM Cryoablation System. This investment is expected to accelerate the progress of its clinical studies and potentially facilitate future market expansion for its advanced cardiac arrhythmia solutions, thereby enhancing patient care. This funding round underscores investor confidence in Adagio Medical’s innovative technology and its potential to address a critical medical need within the broader cardiac care landscape. The company aims to further develop its ULTC platform, expand the indications for its vCLASTM system, and strengthen its market presence. With this new capital, Adagio Medical is positioned to continue its trajectory toward bringing advanced treatment options to patients suffering from complex cardiac arrhythmias, supporting its ongoing growth plans and commercialization strategy.